194,916 Shares in Artivion, Inc. (NYSE:AORT) Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. acquired a new position in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 194,916 shares of the company's stock, valued at approximately $5,573,000. Point72 Asset Management L.P. owned 0.46% of Artivion at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. ProShare Advisors LLC boosted its position in Artivion by 44.7% during the fourth quarter. ProShare Advisors LLC now owns 11,924 shares of the company's stock valued at $341,000 after purchasing an additional 3,683 shares during the last quarter. Millennium Management LLC boosted its position in Artivion by 25.1% during the fourth quarter. Millennium Management LLC now owns 165,482 shares of the company's stock valued at $4,731,000 after purchasing an additional 33,220 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Artivion by 3.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock valued at $645,000 after purchasing an additional 727 shares during the last quarter. Lazard Asset Management LLC boosted its position in Artivion by 28.1% during the fourth quarter. Lazard Asset Management LLC now owns 21,354 shares of the company's stock valued at $610,000 after purchasing an additional 4,686 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in Artivion by 45.1% during the fourth quarter. Deutsche Bank AG now owns 36,982 shares of the company's stock valued at $1,057,000 after purchasing an additional 11,501 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Marshall S. Stanton sold 10,548 shares of Artivion stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $29.13, for a total transaction of $307,263.24. Following the completion of the sale, the senior vice president now directly owns 105,332 shares of the company's stock, valued at approximately $3,068,321.16. This trade represents a 9.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $1,151,280.36. Following the sale, the chief executive officer now directly owns 663,882 shares of the company's stock, valued at approximately $18,130,617.42. The trade was a 5.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 111,273 shares of company stock valued at $2,951,340. Insiders own 7.60% of the company's stock.

Artivion Stock Performance

Shares of AORT traded up $0.18 during mid-day trading on Friday, reaching $28.64. The company's stock had a trading volume of 241,597 shares, compared to its average volume of 326,494. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $32.33. The stock has a market cap of $1.22 billion, a P/E ratio of -1,432.00 and a beta of 1.54. The business has a 50-day simple moving average of $25.13 and a two-hundred day simple moving average of $27.34. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. As a group, equities research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Needham & Company LLC reissued a "buy" rating and set a $32.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Citizens Jmp raised Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Stifel Nicolaus reduced their price target on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Finally, JMP Securities reissued a "market outperform" rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Artivion has a consensus rating of "Buy" and a consensus price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.